Foundation for promotion cardiology / стр. 7 из 30 / Archive / Foundation for Promotion of Cardiology

Main news

PRESS RELEASE OF THE CARDIOPROGRESS FOUNDATION

Main results of the XI International Forum

for Cardiology and Internal Medicine

Shingles vaccine protects against cardiovascular diseases Shingles vaccination reduced major adverse cardiac events and secondary cardiovascular outcomes for patients with atherosclerotic cardiovascular disease, according to new research.

Heart failure evidence update 2026 The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction spectrum.

Editorial Activity

cardiology book

AHA Advisory Endorses Endovascular Thrombectomy for Large Core Ischemic Stroke Results of six recent trials of endovascular thrombectomy (EVT) for patients with large-core ischemic stroke (LCIS) provide strong evidence for the benefit of this intervention compared with medical management (MM), a new Science Advisory from the American Heart Association (AHA) has concluded.

AI-Enhanced ECG Predicts Hypertension, Related Risks An artificial intelligence–ECG risk estimation model designed to predict incident hypertension (AIRE-HTN) identifies cases and stratifies the risk for adverse outcomes in addition to traditional markers.

CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The American Diabetes Association (ADA)’s Standards of Care — 2025 offer new guidance on broader use of continuous glucose monitoring (CGM), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) beyond weight loss, management of metabolic dysfunction-associated liver disease (MAFLD), plus a strong endorsement for drinking water and much more.

ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.

New Trial Result Pushes Past Antiarrhythmic Therapy After MI For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.

New Pill Successfully Lowers Lp(a) Levels Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show.

The results of the 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology 2024 The anniversary 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology were held in Beijing at the National Exhibition Center on November 7-10, 2024. As part of the four-day congress, 415 scientific sessions were organized and 2177 reports were made on various areas of cardiology. The congress was attended by 23,980 national and international experts, professors and specialists from almost 40 countries from all the continents of the world.

New State Law Will Restrict AI in Prior Authorization, Coverage Decisions California is taking aim at algorithms used by insurers to make prior authorization and other coverage decisions with a new law that will put limitations on how artificial intelligence (AI)–generated formulas are employed.

Scientific news

Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

Partners

Video resource

Channel "Cardioprogress"

CARDIOPROGRESS
Foundation for the advancement of cardiology